You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Through Wamberg Genomic Advisors, SCOR life insurance policyholders can access genetic testing to better understand their own cancer risk and therapy options.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.
Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.
Though Guardant and Foundation have pioneered a path through the FDA for liquid biopsy tests, label differences highlight complex choices for oncologists.